CN105521302A - Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus - Google Patents

Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus Download PDF

Info

Publication number
CN105521302A
CN105521302A CN201610020138.7A CN201610020138A CN105521302A CN 105521302 A CN105521302 A CN 105521302A CN 201610020138 A CN201610020138 A CN 201610020138A CN 105521302 A CN105521302 A CN 105521302A
Authority
CN
China
Prior art keywords
parts
chinese medicine
lupus erythematosus
systemic lupus
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610020138.7A
Other languages
Chinese (zh)
Inventor
刘成侠
张靖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Huazhicao Medical Technology Co Ltd
Original Assignee
Qingdao Huazhicao Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Huazhicao Medical Technology Co Ltd filed Critical Qingdao Huazhicao Medical Technology Co Ltd
Publication of CN105521302A publication Critical patent/CN105521302A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/808—Scrophularia (figwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses applications of a traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus, relating to the technical field of traditional Chinese medicines. The traditional Chinese medicinal composition is prepared by taking herba artemisiae annuae, cortex moutan, herba epimedii, herba dendrobii, the root of bidentate achyranthes, lotus plumule, suberect spatholobus stem, dried tangerine or orange peel, radix salviae miltiorrhizae, honeysuckle flowers, radix paeoniae rubra, poria cocos, rhizoma pinelliae, radix codonopsis, semen plantaginis and radix scrophulariae as raw materials. The traditional Chinese medicinal composition can alleviate the pain of a patient suffering from systemic lupus erythematosus, and the medicine for treating systemic lupus erythematosus has the significant activity for regulating T cell sub-groups, is significant in curative effect, is safe and reliable, and has wide clinical application prospect.

Description

The application of a kind of Chinese medicine composition in the medicine preparing systemic lupus erythematosus
The application is the divisional application of the application for a patent for invention (denomination of invention is: a kind of Chinese medicine composition of systemic lupus erythematosus, and application number is: 2014100008412, and the applying date is: on January 2nd, 2014) that applicant Wang Xueyan proposes.
Technical field
The invention belongs to medical art, relate to the application of a kind of Chinese medicine composition in the medicine preparing systemic lupus erythematosus.
Background technology
Systemic lupus erythematosus (sle) (systemiclupuserythematosus, SLE) be a kind of diffusivity, systemic autoimmune diseases, mainly involve mucocutaneous, skeletal muscle, kidney and central nervous system, also lung may be involved simultaneously, heart, multiple organ such as blood and system, show various clinical symptoms, its cause of disease and pathogeny are still not clear, multiple autoantibody and crucial immunological abnormality can be detected in Serum in Patients with SLE, lymphocyte function exception and cytokine profiles secretion is unbalance plays an important role in the developing of this disease, CD3+CD4+T cell in research authentication system lupus erythematosus disease human peripheral is had to decline, CD3+CD8+T rises, IL-10 level raises, wherein IL-10 receives much attention in SLE pathogenesis as the representative of Th type cytokines.Interleukin is the polypeptide class of the non-homogeneous adjustment Growth of Cells of a large class, differentiation, mediation signal transmission, and IL-10 is more concerned in systemic lupus erythematosus (sle) research.IL-10 is a pleiotropic cytokines, and have immunostimulation and immunosuppressant dual function, its immunostimulation mainly improves the survival rate of B cell, promotes the secretion of the expression of the propagation of B cell, MHC-class Ⅱ antigens and antibody.There are some researches show that IL-10 can produce Anti-hCG action by stimulating system patients with SLE PBMCs, no matter Patients with SLE is in active stage or catabasis, and in its body, IL-l0 level is all the time higher than normal person.
Systemic lupus erythematosus (sle) there is no radical cure way at present, the long-term even life-long therapy of a lot of needs of patients.Doctor trained in Western medicine controls the therapy of systemic lupus erythematosus (sle) many employings hormone, hormone is controlled systemic lupus erythematosus (sle) and is had distinguished curative effect, but hormone has sizable side effect, and use hormones a large amount of is for a long time unfavorable for the physical and mental health of patient, moreover, subtracting of hormone stops very likely causing aggravation.The way of middle treatment systemic lupus erythematosus (sle) many employings Chinese drugs dispensing, though Chinese drugs dispensing controls systemic lupus erythematosus (sle) have distinguished curative effect, but curative effect only rests on relief of symptoms side, be difficult to fundamentally treat systemic lupus erythematosus (sle), middle treatment systemic lupus erythematosus (sle) is a long-term process, just sees curative effect after generally adhering to treating half a year.Therefore, all there is certain limitation in the Therapeutic Method of current systemic lupus erythematosus (sle).Find a kind of new active drug to carry out systemic lupus erythematosus patient and have very important meaning.
Summary of the invention
In order to make up the deficiencies in the prior art, the misery of mitigation system patients with SLE, the invention provides a kind of Chinese medicine composition of systemic lupus erythematosus, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
A Chinese medicine composition for systemic lupus erythematosus, this Chinese medicine composition is made up of the raw material of following weight portion: Herba Artemisiae Annuae 10-12 part, Cortex Moutan 5-8 part, Herba Epimedii 6-9 part, Herba Dendrobii 3-5 part, Radix Achyranthis Bidentatae 10-12 part, Plumula Nelumbinis 10-12 part, Caulis Spatholobi 3-5 part, Pericarpium Citri Reticulatae 3-5 part, Radix Salviae Miltiorrhizae 10-12 part, Flos Lonicerae 8-10 part, Radix Paeoniae Rubra 6-9 part, Poria 10-12 part, Rhizoma Pinelliae 10-12 part, Radix Codonopsis 10-12 part, Semen Plantaginis 12-15 part, Radix Scrophulariae 9-12 part.
In Chinese medicine composition described above, Radix Glycyrrhizae 5-8 part and Fructus Ligustri Lucidi 12-15 part can also be contained.These two kinds of Chinese medicines can strengthen the therapeutic effect of the above-mentioned Chinese medicine composition of the present invention further.
The present invention also asks to protect above-mentioned Chinese medicine composition preparing the purposes in medicament for treating systemic lupus erythematosus.Test examples 7 of the present invention shows, and in the test of t lymphocyte subset cluster analysis, compared with SLE model group, the CD3+CD4+T cell that the present invention can make SLE sample mice decline rises, and the CD3+CD8+T of rising is declined, and corrects the imbalance state of T cell subgroup; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, the present invention significantly can reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention significantly can reduce albuminous content in SLE mice urine, Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40%-95% is doubly added according to the 4-9 of coarse powder gross weight, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Chinese medicine composition of the present invention, in systemic lupus erythematosus, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and improves the quality of life of patient.
2) multi-medicament component is contained in Chinese medicine composition of the present invention, action target spot is numerous, pharmacological evaluation shows it and existing Therapy for Systemic Lupus Erythematosus medicine has significant synergism in treatment, and can significantly reduce systemic lupus erythematosus disease, improve the compliance of patient.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
One) example of formulations part
Embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 10 parts, Cortex Moutan 5 parts, Herba Epimedii 6 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 10 parts, Plumula Nelumbinis 10 parts, Caulis Spatholobi 3 parts, Pericarpium Citri Reticulatae 3 parts, Radix Salviae Miltiorrhizae 10 parts, Flos Lonicerae 8 parts, Radix Paeoniae Rubra 6 parts, 10 parts, Poria, the Rhizoma Pinelliae 10 parts, Radix Codonopsis 10 parts, Semen Plantaginis 12 parts, Radix Scrophulariae 9 parts.
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly add according to the 4-9 of coarse powder gross weight the alcoholic solution that volumetric concentration is 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 12 parts, Cortex Moutan 8 parts, Herba Epimedii 9 parts, Herba Dendrobii 5 parts, Radix Achyranthis Bidentatae 12 parts, Plumula Nelumbinis 12 parts, Caulis Spatholobi 5 parts, Pericarpium Citri Reticulatae 5 parts, Radix Salviae Miltiorrhizae 12 parts, Flos Lonicerae 10 parts, Radix Paeoniae Rubra 9 parts, 12 parts, Poria, the Rhizoma Pinelliae 12 parts, Radix Codonopsis 12 parts, Semen Plantaginis 15 parts, Radix Scrophulariae 12 parts.
Preparation technology is with embodiment 1.
Embodiment 3 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 11 parts, Cortex Moutan 7 parts, Herba Epimedii 7 parts, Herba Dendrobii 4 parts, Radix Achyranthis Bidentatae 11 parts, Plumula Nelumbinis 11 parts, Caulis Spatholobi 4 parts, Pericarpium Citri Reticulatae 4 parts, Radix Salviae Miltiorrhizae 11 parts, Flos Lonicerae 9 parts, Radix Paeoniae Rubra 8 parts, 11 parts, Poria, the Rhizoma Pinelliae 11 parts, Radix Codonopsis 11 parts, Semen Plantaginis 13 parts, Radix Scrophulariae 10 parts.
Preparation technology is with embodiment 1.
Embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 10 parts, Cortex Moutan 5 parts, Herba Epimedii 6 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 10 parts, Plumula Nelumbinis 10 parts, Caulis Spatholobi 3 parts, Pericarpium Citri Reticulatae 3 parts, Radix Salviae Miltiorrhizae 10 parts, Flos Lonicerae 8 parts, Radix Paeoniae Rubra 6 parts, 10 parts, Poria, the Rhizoma Pinelliae 10 parts, Radix Codonopsis 10 parts, Semen Plantaginis 12 parts, Radix Scrophulariae 9 parts, 5 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 13 parts.
Preparation technology is with embodiment 1.
Embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 12 parts, Cortex Moutan 8 parts, Herba Epimedii 9 parts, Herba Dendrobii 5 parts, Radix Achyranthis Bidentatae 12 parts, Plumula Nelumbinis 12 parts, Caulis Spatholobi 5 parts, Pericarpium Citri Reticulatae 5 parts, Radix Salviae Miltiorrhizae 12 parts, Flos Lonicerae 10 parts, Radix Paeoniae Rubra 9 parts, 12 parts, Poria, the Rhizoma Pinelliae 12 parts, Radix Codonopsis 12 parts, Semen Plantaginis 15 parts, Radix Scrophulariae 12 parts, 8 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 12 parts.
Preparation technology is with embodiment 1.
Embodiment 6 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 11 parts, Cortex Moutan 7 parts, Herba Epimedii 7 parts, Herba Dendrobii 4 parts, Radix Achyranthis Bidentatae 11 parts, Plumula Nelumbinis 11 parts, Caulis Spatholobi 4 parts, Pericarpium Citri Reticulatae 4 parts, Radix Salviae Miltiorrhizae 11 parts, Flos Lonicerae 9 parts, Radix Paeoniae Rubra 8 parts, 11 parts, Poria, the Rhizoma Pinelliae 11 parts, Radix Codonopsis 11 parts, Semen Plantaginis 13 parts, Radix Scrophulariae 10 parts, 6 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 15 parts.
Preparation technology is with embodiment 1.
(2) test examples part
Embodiment 7 Chinese medicine composition composition injection is on the impact of systemic lupus erythematosus (sle) MRL/lpr mice
1. test material
1.1 laboratory animals and grouping
8 week age, systemic lupus erythematosus (sle) (SLE) MRL/lpr mice 50, female, provided, after adaptability raises one week, be divided into 5 groups at random by body weight by Shanghai Slac Experimental Animal Co., Ltd., often organizes 10.ICR mice 10, female, as Normal group mice.
Normal group: gavage gives solvent;
SLE model group: gavage gives solvent;
Prednisone group: gavage gives 5mg/kg;
Chinese medicine composition low dose group: gavage gives medicine 0.5mg/kg prepared by the embodiment of the present invention 1;
Dosage group in Chinese medicine composition: gavage gives medicine 1mg/kg prepared by the embodiment of the present invention 1;
Chinese medicine composition high dose group: gavage gives medicine 4mg/kg prepared by the embodiment of the present invention 1.
All test group administration every day 1 time, successive administration 3 weeks, gets blood for subsequent use, wins spleen at the end of administration.
1.2 reagent
(1) IL-10, anti-ds-DNA antibody test kit are purchased from Shanghai Ke Feng biological reagent company limited.
(2) PBS: take following reagent 8.5gNaCl, 0.2gKCl, 2.85gNa 2hPO 412H 2o, 0.27gKH 2pO 4, with 1L distilled water standardize solution, above reagent is all be commercially available analytical pure.
(3) erythrocyte cracked liquid: first prepare 0.83%NH 4cl, then prepare tris solution (take tris20.594g to be dissolved in 500-700ml distilled water, then adjust pH7.65 to 1L with 1MHCl), 0.83%NH 4cl and tris solution in 9:1 ratio mixing after and get final product.
(4) anti-mouse fluorescent-tagged mAbs CD3(FITC), be BeckmanCoulter Products.
(5) anti-mouse fluorescent-tagged mAbs CD4(PE), CD8a(PE), Caltaglaboratories product.
Experimental technique
2.1T lymphocyte subgroup is analyzed
The preparation of Single-cell suspensions: the spleen of mice is put into the culture dish filling cold PBS liquid and cleans, 3mlPBS grinding is added in glass homogenizer, filter with 200 order stainless (steel) wires again, centrifugal for Splenic vessel liquid with rotating speed 1500rpm/min centrifugal 7 minutes, abandon supernatant, and add erythrocyte cracked liquid 2.5ml, mixing, leave standstill and after 2 minutes, add PBS liquid 2ml termination lytic response again, with 1500rpm/min centrifugal 7 minutes again, abandoning supernatant, adds PBS after washing three times, under fluorescence microscope, calculate cell number with PBS.Above operation all need on ice.
Use above Single-cell suspensions, after meter cell number, cell concentration is adjusted to 5 × 10 6cells/ml.Each group is got a wherein mouse boosting cell sample and is done subgroup analysis, and the mouse boosting cell sample of adjusted concentration is added flow cytometry dedicated pipe, and two pipes prepared by every mouse boosting cell sample, and often pipe adds sample 100 μ l.
5 μ lCD3(FITC are added at the first pipe containing sample dedicated pipe) and 3 μ lCD4(PE), the second pipe adds 5 μ lCD3(FITC) and 3 μ lCD8(PE).Room temperature black out hatches 20min, and each pipe adds 500 μ l sheath fluids, vibration mixing.Machine analysis in preparation.
2.2 serum IL-10, anti-ds-DNA antibody assay
Operate by test kit operating instruction.
The mensuration of 2.3 microdose urine proteins:
Experiment reagent: 10%(v/v) glacial acetic acid solution (PH2.8); 0.303mol/L glycine-glacial acetic acid buffer (PH3.0): take 22.72g glycine, be diluted to 1000ml with 10% glacial acetic acid solution, add NaN 3100mg, Room-temperature seal Absorbable organic halogens 1 year; Bromophenol blue (1.924mmol/L) stock solution: accurately take 257.36mgBPB, molten to 200ml with dehydrated alcohol, 4 DEG C of refrigerator Absorbable organic halogens 1 year; Bromophenol blue (0.231mmol/L) developer: get 60mlBPB stock solution, add 2.5mlTritonX-100, be diluted to 500ml with glycine-glacial acetic acid buffer, Room-temperature seal can preserve 1 year.
The collection of specimen and detection: in the 20th day mice is put in metabolic cage respectively and raises, collect 12 hours overnight urine, accurate recording urine volume.After sodium azide process, centrifugal (2000r/min) 10min, measures the mice urine 2ml of storage, respectively adds developer 1ml, and mixing (preventing bubble), measures absorbance A with ultraviolet spectrophotometer under 600nm.The content size of absorbance A reflection microdose urine protein, A value is less, and microdose urine protein content is lower.
Experimental data carries out statistical procedures in accordance with the following methods: adopt SPSS10.0 statistical software, and calculate data and represent with mean ± standard deviation (x ± s), many groups data compares employing variance analysis, compares and adopt t inspection in group.With p < 0.05 for there being statistical significance.
Experimental result
3.1 the present invention are on the impact of SLE T lymphocyte subsets in spleen of mice immunized
CD3+CD4+ lymphocyte is helper T lymphocyte (Th), CD3+CD8+ lymphocyte mainly plays inhibition regulating action, SLE mouse model group CD3+CD4+ lymphocyte level is than the decline of Normal group, SLE mouse model group CD3+CD8+ lymphocyte level is than the rising of Normal group, the CD3+CD4+T cell that the present invention can make SLE mice decline rises, the CD3+CD8+T of rising is declined, wherein in Chinese medicine composition, dosage group effect is better, this shows, medicine of the present invention can correct the imbalance state of SLE mouse T cell subgroup.Result of the test is in table 1.
Table 1 the present invention is on the impact of SLE T lymphocyte subsets in spleen of mice immunized
3.2 the present invention are on the impact of serum IL-10, anti-ds-DNA antibody content
Compare with Normal group, IL-10 and the anti-ds-DNA antibody level of SLE model mice obviously raise, compared with SLE model group, the present invention significantly can reduce SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition.This shows, medicine of the present invention is remarkable for SLE mice therapeutic effect.Result of the test is in table 2.
Table 2 the present invention is on the impact of SLE mice serum IL-10, anti-ds-DNA antibody content
*compared with Normal group, p < 0.05; *compared with Normal group, p < 0.01;
#compared with SLE model group, p < 0.05; ##compared with SLE model group, p < 0.01.
3.3 the present invention are on the impact of SLE mouse retention microalbumin content
Microalbuminuria reflection renal abnormality leaky protein, only occur minute quantity albumin in Normal group urine, SLE model group albumin content obviously raises, and reflection SLE mouse kidney has damage; Compared with model group, the present invention significantly can reduce albuminous content in SLE mice urine, and Chinese medicine composition low, middle dosage group effect is particularly remarkable, is better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference.This shows further, and medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.Result of the test is in table 3.
Table 3 the present invention on the impact of SLE mouse retention microalbumin content ( ± S)
*compared with Normal group, p<0.05; *compared with Normal group, p<0.01;
#compared with SLE model group, p<0.05; ##compared with SLE model group, p<0.01.
In the test of t lymphocyte subset cluster analysis, compared with SLE model group, the CD3+CD4+T cell that the present invention can make SLE sample mice decline rises, and the CD3+CD8+T of rising is declined, and corrects the imbalance state of T cell subgroup; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, the present invention significantly can reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention significantly can reduce albuminous content in SLE mice urine, Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.

Claims (3)

1. the application of Chinese medicine composition in the medicine preparing systemic lupus erythematosus, is characterized in that described Chinese medicine composition is obtained by the raw material of following weight portion: Herba Artemisiae Annuae 10 parts, Cortex Moutan 5 parts, Herba Epimedii 6 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 10 parts, Plumula Nelumbinis 10 parts, Caulis Spatholobi 3 parts, Pericarpium Citri Reticulatae 3 parts, Radix Salviae Miltiorrhizae 10 parts, Flos Lonicerae 8 parts, Radix Paeoniae Rubra 6 parts, 10 parts, Poria, the Rhizoma Pinelliae 10 parts, Radix Codonopsis 10 parts, Semen Plantaginis 12 parts, Radix Scrophulariae 9 parts.
2. the application of Chinese medicine composition in the medicine preparing systemic lupus erythematosus as claimed in claim 1, it is characterized in that: described Chinese medicine composition is obtained by following steps: take traditional Chinese medicinal material raw materials by weight and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; This Chinese medical concrete basis prepares conventional Chinese medicine pharmaceutical dosage form clinically.
3. the application of Chinese medicine composition in the medicine preparing systemic lupus erythematosus as claimed in claim 1, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
CN201610020138.7A 2014-01-02 2014-01-02 Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus Withdrawn CN105521302A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410000841.2A CN103705754B (en) 2014-01-02 2014-01-02 A kind of Chinese medicine composition of systemic lupus erythematosus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201410000841.2A Division CN103705754B (en) 2014-01-02 2014-01-02 A kind of Chinese medicine composition of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CN105521302A true CN105521302A (en) 2016-04-27

Family

ID=50399341

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201610020140.4A Withdrawn CN105434894A (en) 2014-01-02 2014-01-02 Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus
CN201610020138.7A Withdrawn CN105521302A (en) 2014-01-02 2014-01-02 Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus
CN201410000841.2A Active CN103705754B (en) 2014-01-02 2014-01-02 A kind of Chinese medicine composition of systemic lupus erythematosus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610020140.4A Withdrawn CN105434894A (en) 2014-01-02 2014-01-02 Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410000841.2A Active CN103705754B (en) 2014-01-02 2014-01-02 A kind of Chinese medicine composition of systemic lupus erythematosus

Country Status (1)

Country Link
CN (3) CN105434894A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109172724A (en) * 2018-11-19 2019-01-11 亳州市君臣佐使药业有限公司 A kind of Chinese materia medica preparation and preparation method thereof for treating lupus erythematosus

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104547674A (en) * 2014-12-24 2015-04-29 广东聚智诚科技有限公司 New application of traditional Chinese medicinal composition
CN104825690A (en) * 2015-05-30 2015-08-12 青岛辰达生物科技有限公司 Traditional Chinese medicine composition for treating lupus nephritis and application thereof
CN104940492A (en) * 2015-07-27 2015-09-30 青岛云天生物技术有限公司 Traditional Chinese medicine composition for treating systemic lupus erythematosus
CN105288473A (en) * 2015-10-30 2016-02-03 江崇礼 Traditional Chinese medicine composition for treating lupus erythematosus and application thereof
CN106177335A (en) * 2016-08-24 2016-12-07 南阳医学高等专科学校 A kind of pharmaceutical composition of systemic lupus erythematosus and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670831A (en) * 2012-05-28 2012-09-19 石家庄平安医院有限公司 Medicinal composition for treating dermatomyositis and preparation method thereof
CN103417531A (en) * 2012-05-14 2013-12-04 鲁南制药集团股份有限公司 Application of arctigenin to preparing medicaments for treating systemic lupus erythematosus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048899C (en) * 1995-04-03 2000-02-02 刘枝芳 Lupus powder medicine and its preparation method
CN1422643A (en) * 2001-12-06 2003-06-11 高大海 Oral pill for treating lupus erythematosus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103417531A (en) * 2012-05-14 2013-12-04 鲁南制药集团股份有限公司 Application of arctigenin to preparing medicaments for treating systemic lupus erythematosus
CN102670831A (en) * 2012-05-28 2012-09-19 石家庄平安医院有限公司 Medicinal composition for treating dermatomyositis and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109172724A (en) * 2018-11-19 2019-01-11 亳州市君臣佐使药业有限公司 A kind of Chinese materia medica preparation and preparation method thereof for treating lupus erythematosus

Also Published As

Publication number Publication date
CN103705754B (en) 2016-03-30
CN105434894A (en) 2016-03-30
CN103705754A (en) 2014-04-09

Similar Documents

Publication Publication Date Title
CN103705754B (en) A kind of Chinese medicine composition of systemic lupus erythematosus
CN101310751B (en) Detection method of medicine composition for replenishing qi and blood
CN105030562B (en) A kind of antiallergy complex polysaccharide composition and its preparation method and application
CN108143825B (en) Medicine for treating psoriasis, preparation method and detection method thereof
CN112755160A (en) Traditional Chinese medicine composition for improving postoperative prognosis of breast cancer and application thereof
CN104940599A (en) Application of traditional Chinese medicine composition in preparation of medicines for improving lipid metabolism
CN111437338A (en) Application of traditional Chinese medicine composition in treating skin diseases
CN103417531B (en) The purposes of arctigenin in the medicine preparing systemic lupus erythematosus
CN104547514A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN102652774B (en) Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method
CN102846732A (en) A Chinese medicine composition for the treatment of breast hyperplasia and its preparation method
CN102641402B (en) Preparation method of traditional Chinese medicine compound preparation for treating nephritis
CN100998687B (en) Medicine composition for treating chronic gastritis, and its preparing process
CN105477361B (en) A kind of Chinese medicine composition preparation method that treating gastritis and preparation
CN104825690A (en) Traditional Chinese medicine composition for treating lupus nephritis and application thereof
CN104547674A (en) New application of traditional Chinese medicinal composition
CN109550035B (en) New application of traditional Chinese medicine composition in preparation of antidepressant
CN102188592A (en) Medicine for treating thrombocytopenia after tumor chemotherapy and preparation method thereof
CN101099799B (en) Medicine for treating leucoderma by melanin regeneration
CN104524338B (en) A kind of Chinese medicine that treating IgA nephrosis and its application
CN104688723A (en) Application of anhydroicaritin in preparation of medicine for treating anaemia
CN104706708B (en) Red stilbene ethanol extract prevents and treats application and wherein effective component identification method in hepatic fibrosis medicines in preparation
CN114344388B (en) Traditional Chinese medicine composition for treating insomnia and application thereof
CN108403793B (en) Medicine for treating primary dysmenorrhea and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Wang Xia

Inventor after: Li Ping

Inventor after: Liu Chengxia

Inventor after: Zhang Jing

Inventor before: Liu Chengxia

Inventor before: Zhang Jing

CB03 Change of inventor or designer information
WW01 Invention patent application withdrawn after publication

Application publication date: 20160427

WW01 Invention patent application withdrawn after publication